Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

Will Lewis, Chair and Chief Executive Officer of Insmed

“The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline. BRINSUPRI's U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market. This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products. We were also pleased to receive regulatory approval and launch BRINSUPRI in Japan, a profound milestone for patients living with bronchiectasis. In addition, the FDA's acceptance of the sNDA for ARIKAYCE in MAC lung disease represents an important step toward expanding access to this therapy for eligible patients, including those that are newly diagnosed or facing recurrent infections. As we advance our Phase 3 TPIP programs across four large indications and progress our early-stage pipeline, we remain focused on delivering meaningful innovation and improving the lives of patients with serious diseases.”